Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy.
Simister, P.C., Border, E.C., Vieira, J.F., Pumphrey, N.J.(2022) J Immunother Cancer 10
- PubMed: 35851311 
- DOI: 10.1136/jitc-2022-004600
- Primary Citation of Related Structures:  
7PBC, 7PDW, 7PDX, 7QPJ - PubMed Abstract: 
T-cell receptor (TCR) immunotherapy is becoming a viable modality in cancer treatment with efficacy in clinical trials. The safety of patients is paramount, so innovative cell engineering methods are being employed to exploit adaptive immunity while controlling the factors governing antigen receptor (ie, TCR) specificity and cross-reactivity ...